Nurse Quality of Life Important Component for Improved Patient Outcomes

Article

According to the research, there are important components and factors missing from the scale commonly used to measure a clinician’s quality of life.

Quality of life (QOL) for nurses, especially an issue like compassion fatigue, is often overlooked as most oncology nurses’ work involves dealing with patients QOL, but it remains significant for clinicians to address their own QOL.

Recent research presented at the 46th Annual Oncology Nursing Society Annual Congress analyzed the Professional QOL (ProQOL) tool that is currently used to better understand nurses’ QOL, compared with the Theory of Oncology Nurses’ Professional QOL.

“[QOL is] really important in helping address patient outcomes, retain oncology nurses – or nurses in general – and improve and maintain our nursing model,” said study co-author Rebecca L. Boni, PhD, RN, ACCNS-AG, OCN, assistant professor at Oakland University, while presenting the findings.

The ProQOL Scale is a 30-question survey that includes 3 subscales: burnout, secondary traumatic stress, and compassion satisfaction. To date, there have been inconsistent findings about nurses’ professional QOL compared to ProQOL findings.

“When we look at the nursing professional quality of life, the literature almost always uses the ProQOL scale,” Boni said. “It was developed for social workers, but it’s used broadly in just about all caring professions: chaplains, teachers, physicians, nurses, social workers, [it’s] all over the board… The problem is, when I looked at the body of literature, there’s a lot of inconsistent findings, whether I look at just nurses or oncology nurses.”

The researchers surveyed 14 oncology nurses from 10 different health systems. Participants were asked to rate their own QOL on a scale of 1 through 10, and complete the ProQOL. Descriptive statistics, which were then used to compare ProQOL scores and qualitative results and self-ratings.

Among the ProQOL items, 26.7% were not related from categories that emerged from the qualitative data reported by the nurses. Additionally, more than half (8 out of 13) of the sub-categories from the study were not addressed within the ProQOL, including:

  • Expecting growth, change, and challenge
  • Knowing the demands
  • Embracing complex relationships with time
  • Pursuing full potential
  • Harmonizing with personal QOL
  • Establishing autonomy
  • Feeling recognized
  • Working cohesively

Ultimately, this study found that the Theory of Oncology Nurses’ Professional QOL is likely a more precise measure of oncology nurses’ QOL than ProQOL.

“If we can better measure professional quality of life and get more consistent research that we can trust, [we can] really develop interventions that can improve professional quality of life,” Boni said. “And from there, we can improve the wellbeing of nurses, improve our patient outcomes, and stabilize the nursing workforce – all of which we know are high priorities.”

Reference

Boni RL, Dingley C. Oncology Nurses’ Professional Quality of Life: An Analysis of Defining and Measuring Professional QOL. Presented at: the 46th Annual ONS Congress; April 22, 2021; virtual.

Recent Videos
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Related Content